An Indication Selection Resource for Longevity Companies

Key Takeaways

• Resource lists 47 age‑related disease indications.
• Includes market size, trial cost, and animal model data.
• Guides startups to select FDA‑approved disease targets.
• Highlights high trial costs and funding requirements.
• Emphasizes unmet need and differentiation for investor appeal.

Pulse Analysis

Bringing a longevity therapy from bench to bedside is fraught with regulatory ambiguity and capital intensity. Traditional biotech pathways rely on clear, FDA‑recognizable endpoints, yet aging itself lacks a reimbursable metric. Norn Group’s new indication‑selection spreadsheet confronts this gap by cataloguing 47 age‑related diseases, each annotated with disease mechanisms, incidence rates, and existing standard‑of‑care therapies. By translating the abstract goal of “longevity” into concrete disease targets, the resource equips founders with a pragmatic roadmap that aligns scientific ambition with the realities of drug approval.

The spreadsheet’s depth goes beyond a simple list; it aggregates market size forecasts, typical trial durations, per‑patient cost ranges ($50K‑$200K), and the suitability of animal models for translational research. Startups can quickly assess whether their biology fits a given indication, gauge the financial runway required for human trials, and identify unmet clinical needs that could differentiate their candidate. This data‑driven approach reduces speculative risk, enabling founders to craft pitch decks that speak directly to investors’ demand for measurable milestones and clear commercialization pathways.

For the broader longevity ecosystem, the tool signals a shift toward disease‑centric development, a trend already evident in companies like BioAge and NewLimit. By lowering the informational barrier to indication selection, Norn Group may accelerate the pipeline of age‑related therapeutics entering Phase II/III studies, ultimately expanding the market for interventions that address multi‑morbidity. Investors, regulators, and payers will likely view this structured methodology as a catalyst for more predictable returns and faster patient access to next‑generation treatments.